The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy

被引:70
作者
Carrier, Lucie [1 ,2 ,3 ]
Schlossarek, Saskia [1 ]
Willis, Monte S. [4 ,5 ]
Eschenhagen, Thomas [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Cardiovasc Res Ctr, Inst Expt & Clin Pharmacol & Toxicol, D-20246 Hamburg, Germany
[2] INSERM, Inst Myol, U974, F-75013 Paris, France
[3] Univ Paris 06, UMR S974, CNRS,IFR14, UMR7215,Inst Myol, F-75013 Paris, France
[4] Univ N Carolina, Carolina Cardiovasc Biol Ctr, Chapel Hill, NC USA
[5] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA
关键词
Hypertrophy; Cardiomyopathy; Ubiquitin-proteasome system; Nonsense-mediated mRNA decay; BINDING-PROTEIN-C; SPLICE DONOR SITE; CARDIAC-HYPERTROPHY; PROTEOLYTIC FUNCTION; SEPTAL HYPERTROPHY; DIAGNOSTIC-VALUE; IN-VIVO; MUTATIONS; GENE; EXPRESSION;
D O I
10.1093/cvr/cvp247
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiomyopathies represent an important cause of cardiovascular morbidity and mortality due to heart failure, arrhythmias, and sudden death. Most forms of hypertrophic cardiomyopathy (HCM) are familial with an autosomal-dominant mode of inheritance. Over the last 20 years, the genetic basis of the disease has been largely unravelled. HCM is considered as a sarcomeropathy involving mutations in sarcomeric proteins, most often beta-myosin heavy chain and cardiac myosin-binding protein C. 'Missense' mutations, more common in the former, are associated with dysfunctional proteins stably integrated into the sarcomere. 'Nonsense' and frameshift mutations, more common in the latter, are associated with low mRNA and protein levels derived from the diseased allele, leading to haploinsufficiency of the remaining healthy allele. The two quality control systems responsible for the removal of the affected mRNAs and proteins are the nonsense-mediated mRNA decay (NMD) and the ubiquitin-proteasome system (UPS), respectively. This review discusses clinical and genetic aspects of HCM and the role of NMD and UPS in the regulation of mutant proteins, evidence for impairment of UPS as a pathogenic factor, as well as potential therapies for HCM.
引用
收藏
页码:330 / 338
页数:9
相关论文
共 92 条
[1]   Genetic basis of hypertrophic cardiomyopathy: From bench to the clinics [J].
Alcalai, Ronny ;
Seidman, Jonathan G. ;
Seidman, Christine E. .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2008, 19 (01) :104-110
[2]   Ubipuitin-Proteasome System Impairment Caused by a Missense Cardiac Myosin-binding Protein C Mutation and Associated with Cardiac Dysfunction in Hypertrophic Cardiomyopathy [J].
Bahrudin, Udin ;
Morisaki, Hiroko ;
Morisaki, Takayuki ;
Ninomiya, Haruaki ;
Higaki, Katsumi ;
Nanba, Eiji ;
Igawa, Osamu ;
Takashima, Seiji ;
Mizutas, Einosuke ;
Miake, Junichiro ;
Yamamoto, Yasutaka ;
Shirayoshi, Yasuaki ;
Kitakaze, Masafumi ;
Carrier, Lucie ;
Hisatome, Ichiro .
JOURNAL OF MOLECULAR BIOLOGY, 2008, 384 (04) :896-907
[3]   Enhanced ubiquitination of cytoskeletal proteins in pressure overloaded myocardium. is accompanied by changes in specific E3 ligases [J].
Balasubramanian, Sundaravadivel ;
Mani, Santhoshkumar ;
Shiraishi, Hirokazu ;
Johnston, Rebecca K. ;
Yamane, Kentaro ;
Willey, Christopher D. ;
Cooper, George ;
Tuxworth, William J. ;
Kuppuswamy, Dhandapani .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2006, 41 (04) :669-679
[4]   Dilated-hypokinetic evolution of hypertrophic cardiomyopathy - Prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients [J].
Biagini, E ;
Coccolo, F ;
Ferlito, M ;
Perugini, E ;
Rocchi, G ;
Bacchi-Reggiani, L ;
Lofiego, C ;
Boriani, G ;
Prandstraller, D ;
Picchio, FM ;
Branzi, A ;
Rapezzi, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (08) :1543-1550
[5]   Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy [J].
Birks, Emma J. ;
Latif, Najma ;
Enesa, Karine ;
Folkvang, Tonje ;
Luong, Le Anh ;
Sarathchandra, Padmini ;
Khan, Mak ;
Ovaa, Huib ;
Terracciano, Cesare M. ;
Barton, Paul J. R. ;
Yacoub, Magdi H. ;
Evans, Paul C. .
CARDIOVASCULAR RESEARCH, 2008, 79 (03) :472-480
[6]   Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins [J].
Bonuccelli, G ;
Sotgia, F ;
Schubert, W ;
Park, DS ;
Frank, PG ;
Woodman, SE ;
Insabato, L ;
Cammer, M ;
Minetti, C ;
Lisanti, MP .
AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (04) :1663-1675
[7]  
Bottinelli R, 1998, CIRC RES, V82, P106
[8]   Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice [J].
Carrier, L ;
Knöll, R ;
Vignier, N ;
Keller, DI ;
Bausero, P ;
Prudhon, B ;
Isnard, R ;
Ambroisine, ML ;
Fiszman, M ;
Ross, J ;
Schwartz, K ;
Chien, KR .
CARDIOVASCULAR RESEARCH, 2004, 63 (02) :293-304
[9]   Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy [J].
Carrier, L ;
Bonne, G ;
Bahrend, E ;
Yu, B ;
Richard, P ;
Niel, F ;
Hainque, B ;
Cruaud, C ;
Gary, F ;
Labeit, S ;
Bouhour, JB ;
Dubourg, O ;
Desnos, M ;
Hagege, AA ;
Trent, RJ ;
Komajda, M ;
Fiszman, M ;
Schwartz, K .
CIRCULATION RESEARCH, 1997, 80 (03) :427-434
[10]  
Carrier L, 2007, ARCH MAL COEUR VAISS, V100, P238